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Abstract
Background: Combining gene expression microarrays and high resolution magic angle spinning magnetic
resonance spectroscopy (HR MAS MRS) of the same tissue samples enables comparison of the transcriptional and
metabolic profiles of breast cancer. The aim of this study was to explore the potential of combining these two
different types of information.
Methods: Breast cancer tissue from 46 patients was analyzed by HR MAS MRS followed by gene expression
microarrays. Two strategies were used to combine the gene expression and metabolic data; first using multivariate
analyses to identify different groups based on gene expression and metabolic data; second correlating levels of
specific metabolites to transcripts to suggest new hypotheses of connections between metabolite levels and the
underlying biological processes. A parallel study was designed to address experimental issues of combining
microarrays and HR MAS MRS.
Results: In the first strategy, using the microarray data and previously reported molecular classification methods,
the majority of samples were classified as luminal A. Three subgroups of luminal A tumors were identified based
on hierarchical clustering of the HR MAS MR spectra. The samples in one of the subgroups, designated A2, showed
significantly lower glucose and higher alanine levels than the other luminal A samples, suggesting a higher
glycolytic activity in these tumors. This group was also enriched for genes annotated with Gene Ontology (GO)
terms related to cell cycle and DNA repair. In the second strategy, the correlations between concentrations of myo-
inositol, glycine, taurine, glycerophosphocholine, phosphocholine, choline and creatine and all transcripts in the
filtered microarray data were investigated. GO-terms related to the extracellular matrix were enriched among the
genes that correlated the most to myo-inositol and taurine, while cell cycle related GO-terms were enriched for the
genes that correlated the most to choline. Additionally, a subset of transcripts was identified to have slightly
altered expression after HR MAS MRS and was therefore removed from all other analyses.
Conclusions: Combining transcriptional and metabolic data from the same breast carcinoma sample is feasible
and may contribute to a more refined subclassification of breast cancers as well as reveal relations between
metabolic and transcriptional levels.
See Commentary: http://www.biomedcentral.com/1741-7015/8/73
Background
Transcriptomics and metabolomics in cancer research
have traditionally been considered as two separate fields.
Different levels of the molecular processes are studied,
aiming at improving cancer treatment by understanding
the underlying mechanisms of the disease. Breast cancer
treatment decisions today are mainly based on tumor
size, histological characterization, grading and receptor
status, as well as axillary lymph node status, and age of
the patients [1]. However, patients with similar diagnosis
and treatment can experience large differences in the
progression and relapse of their disease. The various
-omics fields, transcriptomics in particular, have pro-
vided an understanding of breast cancer as a group of
molecularly distinct neoplastic disorders [2]. Clinical use
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potential to stratify breast cancer patients for more indi-
vidual treatment, but has so far only been implemented
to a limited extent.
The field of transcriptomics, using DNA microarrays
that enable measurements of thousands of RNA tran-
scripts in a single experiment, has had a huge impact on
breast cancer research over the last decade [2]. One of
the important findings has been the classification of
breast cancer into five subtypes (luminal A, luminal B,
basal-like, ERBB2 enriched and normal-like) based on
gene expression profiles of so called intrinsic genes
[3,4]. This molecular subtyping of breast cancer, has
been reproduced in several studies and is also associated
with clinical outcome across datasets [5,6].
Metabolomics studies the metabolites and how they
are affected by specific cellular processes. The possibility
of using in vivo magnetic resonance spectroscopy (MRS)
as a diagnostic, prognostic or predictive tool in the
clinic simultaneously with an MR imaging (MRI) exami-
nation, makes MRS techniques attractive methods for
molecular classification of disease. Metabolic profiling of
intact biological samples using high resolution magic
angle spinning magnetic resonance spectroscopy (HR
MAS MRS) enables measurement of multiple cellular
metabolites simultaneously. The method has been uti-
lized in a wide range of biological applications [7], and
studies of cancers have proven HR MAS MRS to be a
promising tool in cancer diagnosis and treatment moni-
toring [8]. Importantly, the sample is kept intact
throughout the HR MAS MRS analysis and can subse-
quently be analyzed by gene expression analysis.
Profiling gene expression and metabolite content in
the same breast carcinoma samples enables comparisons
of molecular findings at different levels. Gene expression
data and metabolite data from MRS techniques of differ-
ent samples from the same breast cancer cell line or
xenograft model have been combined previously [9-12],
but these studies have mainly focused on specific genes
involved in choline metabolism, known as the Kennedy
pathway. Combining transcriptomic and metabolomic
profiling of the same sample allow us to capture a com-
prehensive picture at a given moment in time. Such stu-
dies could reveal differences and similarities between
groups of samples at different molecular levels and pro-
vide a fundament for enhanced knowledge of the biolo-
gical dynamics of breast cancers.
The aim of this study was to combine gene expression
microarrays and HR MAS MRS for more refined profil-
ing of breast tumors, and to explore some of the poten-
tials and limitations of the experimental procedures.
This study focuses on the most prevalent type of breast
cancer, invasive ductal carcinomas (IDC) with oestrogen
(ER) receptor positive disease, and the largest molecular
subgroup within these tumors, luminal A. ER positive
breast cancer accounts for approximately 2/3 of the
cases, and although they overall have a relatively good
prognosis, some patients experience relapse and do not
respond to antieostrogen treatment. So far there are no
biomarkers available to identify those patients and no
targets for therapy, and identification of molecular mar-
kers of such tumors, possibly by metabolic profiling, are
therefore of high relevance. Identifying subgroups of
patients within this group is an important goal to make
it possible to further individualize cancer diagnosis and
treatment.
Methods
Patients
Tissue samples were selected from a local breast cancer
tissue bank, obtained from patients with palpable breast
lesions who underwent scheduled surgery for breast
cancer at St. Olavs University Hospital in Trondheim,
Norway (March 2000 - March 2004). Samples were
placed in cryogenic vials and immersed in liquid nitro-
gen immediately after dissection. In this study we
selected samples from patients diagnosed with IDC, who
did not receive any treatment prior to surgery. Clinical
data of the patients, such as diagnosis, tumor grade,
tumor size, hormone receptor status and lymph node
involvement were obtained from patient records, includ-
ing pathology reports, and are summarized in Table 1.
The Regional Committee for Medical and Health
Research Ethics approved the study protocol, and all
patients provided written informed consent.
Sample preparation and experimental design
An illustration of the experimental workflow as well as
the data analysis for this study is shown in Figure 1.
Tumor tissue samples from 46 patients were cut from
each tumor and analyzed by HR MAS MRS. Proceeding
HR MAS MRS, the tissue was directly snap frozen and
later used to extract RNA for microarray analysis. For
11 of the tissue samples, the quality of RNA obtained
after HR MAS MRS analysis was of insufficient quality,
and adjacent tissue from the same tumors, not subjected
to HR MAS MRS, was used for RNA extraction and
microarray analysis. Additionally, histopathology was
performed on adjacent tumor tissue for each sample, as
described previously [13], to assess the percentage of
cancer cells in each sample. The samples contained on
average 23% tumor cells with a range of 0-80%.
HR MAS MRS experiments
Sample preparation and HR MAS MRS experiments
were performed as previously described [13]. In brief, all
samples were cut to fit a 4 mm o.d. rotor with inserts
(total sample volume 50 μL). Samples analyzed by HR
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The remaining rotor volume was filled with buffer
(phosphate buffered saline (PBS) in D2Oc o n t a i n i n gt r i -
methylsilyl tetradeuteropropionic acid (TSP)). HR MAS
MRS experiments were performed on a Bruker Avance
DRX600 spectrometer equipped with a
1H/
13CM A S
probe (Bruker BioSpin GmbH, Germany). Samples were
spun at 5 kHz while keeping the temperature at 4°C.
Two types of one-dimensional
1H spectra were
recorded, a single pulse experiment with water suppres-
sion and a spin-echo experiment (CPMG) for suppres-
sion of broad signals from macromolecules. Spectral
assignments were performed based on previous HR
MAS MRS studies of breast cancer lesions [13,14].
RNA extraction and microarrays
Total RNA was extracted from the biopsies that were
used in the HR MAS MRS procedure from each patient,
following the protocol for the RNeasy Mini Kit (Qiagen,
USA). High quality RNA, measured by BioAnalyzer
2100 (Agilent Technologies, USA) was used in microar-
ray experiments, using 44k two-color Agilent Human
Whole Genome Oligo Microarrays. The microarray ana-
lysis was performed according to the manufacturer’s
protocol, using Cy5 labeling for the tumor RNA and
Cy3 for the reference RNA, Universal Human Reference
(Stratagene, USA). Data were extracted from the
microarray images using Feature Extraction Software
v8.5 (Agilent Technologies, USA). The final dataset
included gene expression microarray data from 46
patients, 35 obtained from RNA extracted from the HR
MAS MRS analyzed tissue and 11 from adjacent tumor
tissue, as illustrated in Figure 1.
Preprocessing and normalizing the microarray data
The two-color microarray data were preprocessed and
analyzed in R (v2.8) and Bioconductor, using the Feature
Extraction text files. The red (sample) and green (refer-
ence) signals were set to be g(r)MeanSignal, and the
data were normalized using the Limma package [15].
Each microarray was background corrected by subtract-
ing the g(r)SpatialDetrendSurfaceValue values, and nor-
malized with loess normalization. Normalization
between arrays was performed with Gquantile normali-
zation, which ensures the same empirical distribution
for the green channel and adjusts the red channel
accordingly. The data were log2 transformed and miss-
ing data were imputed using local least squares imputa-
tion from the pcaMethods package [16]. Control probes
and probes which were flagged as outliers on more than
20% of the arrays were removed. The average of dupli-
cate probes was calculated, and the averaged probe
value with the highest IQR was picked to represent each
transcript, when the gene symbol (supplied by Agilent)
was represented by different probes. A subset of 1199
probes that were identified to have an altered gene
expression after HR MAS MRS in a parallel study
described below were also removed.
Subtyping with microarray and HR MAS MRS data
Using gene median centered microarray data, the
expression of “intrinsic” genes of the tumors from all 46
patients were analyzed for Spearman’s correlation to
published centroids of the five intrinsic subtypes [17].
The samples were classified according to the highest
correlation value to the centroids. Prior to subtyping,
probes of bad quality and 9 transcripts identified to
show altered gene expression after HR MAS MRS were
removed from the centroids, resulting in a match of 286
out of 306 intrinsic genes. The threshold for classifica-
tion into a subtype was set to be correlation above 0.1
(One sample showed the same correlation to two sub-
t y p e sa n dw a sr e g a r d e da su n c l a s s i f i e d ) .T h eh i g h
dimensional spin echo spectra (spectral region 4.8 - 1.45
ppm, excluding lipid containing regions at 2.8 ppm and
2.05 ppm, described by 5993 data points) of the 31
tumors classified as luminal A and with tumor cell per-
centage above 5%, were used to assess if adding the
metabolic data revealed additional structure within this
group of tumors. Normalization of the selected spectral
regions was performed by mean normalization.
Table 1 Clinical data on the 46 patients included in the
main study
Characteristics Summary
Age, mean (range) years 64 (30 - 91)
Tumor size, mean (sd) (cm) 2.5 (± 1.4)
Grade
I5
II 17
III 21
NA 3
Axillary lymph node status
Negative 22
Positive 20
NA 4
Oestrogen receptor (ER) status
Negative 5
Positive 41
Progesterone receptor (PgR) status
Negative 9
Positive 36
NA 1
All patients were diagnosed with invasive ductal carcinoma (IDC). All
characteristics, except for age and tumor size, are summarized by number of
patients in each group. ER and PgR were determined by
immunohistochemistry, and samples with ≥10% staining cancer cells were
considered receptor positive.
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microarray and HR MAS MRS data are illustrated schematically.
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age was performed using Spearman’s correlation as simi-
larity measure, identifying three luminal A groups by
c u t t i n gt h ed e n d r o g r a ma th e i g h t0 . 3 9 ,w h i c hw a s
decided as a threshold that gave convincing separation
between groups. Multidimensional scaling (MDS) using
Spearman’s correlation as similarity measure was also
used to assess if the same samples grouped together
when using a different multivariate analysis. To test for
metabolic differences between the three groups, t-tests
were performed between pairs of points in the spectra.
Differential gene expression analysis between the three
identified luminal A groups was performed using the
Limma package (R/Bioconductor) [15]. Modified t-tests
were performed on each gene, with Empirical Bayes cor-
rection of the test statistics and Benjamini and Hoch-
berg adjusted p-values. To assess if sets of genes known
to be involved in the same process, share the same func-
tion or location were concordantly differentially
expressed between the three luminal A groups, Gene
Ontology (GO) [18] enrichment analyses were per-
formed using Gene Set Analysis (GSA) [19]. GSA is a
refined version of the original Gene Set Enrichment
Analysis, which can be used to test if sets of genes are
differentially expressed between two groups, using a
maxmean statistic and permutation analysis to calculate
the p-values. The GSA analysis was run with 10000 per-
mutations, and the raw p-values were used. The Benja-
mini Hochberg false discovery rate was calculated
separately.
Correlation analysis between metabolite concentration
and gene expression
Microarray and HR MAS MRS data from the same sam-
ples of the ER+ tumors with tumor cell percentage > 5%
(N = 34) were used to test for nonzero correlations
between metabolite and gene expression levels (For
seven of the samples, the microarray data were obtained
from adjacent tumor tissue). Quantification of eight tis-
sue metabolites was performed based on peak areas in
the single-pulse spectra and TSP concentrations as in
[13]. After preprocessing the HR MAS MR spectra
(WINNMR, Bruker Biospin GmbH, Germany), peak
areas were calculated for the signals arising from myo-
inositol, taurine, choline, GPC, PCho, glucose, creatine
and glycine using the Voigt (combined Lorentzian and
Gaussian) area function in PeakFit (Seasolve, MA USA).
Quantification of lactate was not performed since lipid
signals concealed the lactate signals (signals from lipid
-CH2 overlap with lactate CH3 and glycerol backbone of
triglycerides overlap with lactate CH) in two thirds of
the spectra. Probes on the microarray with IQR < 0.8
were removed, and Spearman correlation tests between
the 8 metabolites and all of the 13875 unique probes
were performed. For each metabolite, all transcripts
were ranked according to Spearman’s rank correlation
coefficient. The resulting genelists were analyzed for
enriched GO-terms using GOrilla, which searches for
GO-terms that are enriched in the top of the list com-
pared to the rest of the list using the mHG statistics
[20,21].
Assessing the effect of HR MAS MRS on RNA integrity
and transcription
No apparent differences were observed between the
microarray data from the 35 samples that did undergo
HR MAS MRS compared to the 11 samples that did
not. However, to explore this issue more thoroughly, an
additional study was designed to assess the feasibility of
performing gene expression microarrays and HR MAS
MRS on the same sample as well as identify transcripts
that should be filtered out from microarray analyses if
they have been systematically affected by the HR MAS
MRS procedure. This additional study included 18 pairs
of tumor samples, obtained from the local breast cancer
tissue bank described above. One sample from each pair
was analyzed by HR MAS MRS, RNA was isolated from
both samples from each of the 18 pairs, and gene
expression microarray analysis was performed. The HR
MAS MRS experiments were performed as described
above, while the RNA extraction, microarray experi-
ments and preprocessing of the microarray data were
performed using slightly different protocols, as described
in Additional file 1: Supplementary documentation of
exploring the effect of HR MAS MRS on RNA integrity
and transcription. The effect of HR MAS MRS on RNA
integrity was tested using a paired t-test on the RIN-
values measured using Bioanalyzer 2100 (Agilent Tech-
nologies). Unsupervised hierarchical clustering of the
normalized microarray data from the 18 pairs of sam-
ples and modified t-tests were performed [15] to test for
differential gene expression caused by the HR MAS
MRS procedure. The transcripts that showed signifi-
cantly higher or lower (fdr < 0.01) expression in the
samples analyzed by HR MAS MRS, were tested for
enriched GO-terms [22]. Transcripts identified as having
significantly altered expression after HR MAS MRS were
removed from the microarray data in the main study. A
more detailed description of the data analysis from this
additional study can be found in Additional file 1: Sup-
plementary documentation of exploring the effect of HR
MAS MRS on RNA integrity and transcription.
Results
Two main strategies of combining information from the
microarray data with the HR MAS MR spectra are pre-
sented, as shown in the workflow illustrated in Figure 1.
The first strategy uses multidimensional gene expression
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tify molecular subgroups of tumors. The second strategy
compares the quantified concentration of specific meta-
bolites to the expression level of each transcript in the
filtered microarray data. In a parallel study, we per-
formed additional experiments to assess the impact of
sample treatment during HR MAS MRS on RNA integ-
rity and gene expression.
Transcriptional and metabolic subtyping based on high-
dimensional data
Each of the 46 tumor samples (Figure 1), were subtyped
according to the highest Spearman’s correlation of the
expression of intrinsic genes to published centroids
from the five subtypes [17]. This subtyping method
resulted in the tumors being classified into 36 luminal
A, 7 normal-like, 1 ERBB2 enriched, 1 basal-like, and 1
unclassified. The samples classified as luminal A were
all ER positive. The ER-negative samples were classified
as 1 basal-like and 4 normal-like. The HR MAS MR
spectra from the tumors classified as luminal A (n = 31
with tumor cell percentage >5%), were used to search
for diversity within this subgroup in the metabolic data.
Hierarchical clustering based on the HR MAS MR spin
echo spectra revealed three clusters that were convin-
cingly separated when selecting a threshold of the den-
d r o g r a ma th e i g h t0 . 3 9( F i g u r e2 ) .T h es a m p l e s
belonging to each of these three subgroups of luminal A
samples, designated A1, A2 and A3, also clustered
together when applying MDS to the HR MAS MR spec-
tra (Figure 3). Differences in the metabolic and gene
expression profiles between the A1-A3 groups of lumi-
nal A tumors are illustrated in Figure 4. The metabolites
allocated at the points that significantly differed between
the profiles (p < 0.001) include a-glucose, b-glucose,
amino acids (signals from a-H which is the Hydrogen
bonded to the a-C of all amino acids), myo-inositol, ala-
nine and lipid residues [14]. Glucose signals were signifi-
cantly lower in the A2 group compared to the A1 and
A3 luminal tumors. The a-H amino acid signals were
significantly lower in A1 and higher in A3, compared to
A2. Alanine signals were significantly higher in A2 com-
pared to A3. Signals from lipid residues were signifi-
cantly higher and signals from myo-inositol were
significantly lower in A1 than in A2 and A3. Differential
gene expression analysis between the three luminal A
groups, using Limma, resulted in no significant differ-
ences in expression of single genes with fdr < 0.01.
However, when analyzing differences in gene expression
between sets of genes annotated with the same GO-
terms, using GSA, different significantly enriched GO-
terms (fdr < 0.01) were revealed by comparing the three
luminal A groups (Figure 4). The A2 tumors were
enriched for biological processes related to the cell cycle
and DNA repair, namely “Meiosis I”, “Meiotic recombi-
nation” and “Double strand break repair” compared to
t h eA 1t u m o r s .T h eA 3g r o u pw a se n r i c h e df o rt h e
molecular function “Protein C terminus binding” com-
pared to the A2 group. There was not significant evi-
dence of differences in tumor percentage between the
three groups.
Correlating metabolic and transcriptional profiles
The levels of 8 specific metabolites were compared with
the transcriptional activity in each tumor in the ER+
samples (n = 34 with tumor cell percentage >5%). These
samples include the 31 luminal A samples mentioned
above plus three samples that were classified as normal-
like, but also correlated to the luminal A centroid. Tis-
sue concentrations of some of the 8 quantified metabo-
lites co-varied, see Additional file 2: Scatterplot of
metabolite concentrations and tumor percentage. Taur-
ine, myo-inositol and choline correlated significantly
with each other, as did creatine, PCho, GPC and glycine.
Glucose showed a negative or no significant correlation
to all the other metabolites. Lists of all transcripts on
the microarray with IQR > 0.8 (13875 unique probes)
were ranked according to correlation, from high to low,
to each of the 8 metabolites. Plots showing the co-varia-
tion of myo-inositol and choline concentration with the
expression of the transcripts that correlated the most to
these metabolites are shown in Figure 5. The ranked
lists of transcripts were used to test for GO enrichment
towards the top of the list, using GOrilla [20,21]. Signifi-
cantly enriched (fdr < 0.003) GO-terms in the biological
process (BP), cellular component (CC) and molecular
function (MF) GO-categories are given for each metabo-
lite in Table 2. GO-terms related to the extracellular
matrix are enriched towards the top of the lists of tran-
scripts ranked according to correlation to myo-inositol
and taurine. GO-terms related to the cell cycle, such as
“cell cycle process” and “chromosome segregation” are
enriched towards the top of the list of transcripts ranked
according to correlation to choline. The lists of tran-
scripts ranked according to correlation to glucose, crea-
tine and glycine only gave one enriched GO-term each,
“immune system process”, “mannosyltransferase activity”
and “respiratory chain”, respectively. There were no sig-
nificantly enriched GO-terms for the lists of transcripts
ranked according to correlation to GPC and PCho.
Effect of HR MAS MRS on RNA quality and gene
expression
T h ee f f e c to ft h eH RM A SM R Sp r o c e d u r eo nR N A
integrity and transcription in the breast cancer tissue
was assessed separately on 18 pairs of samples. There
was not significant evidence that total RNA integrity,
quantified by the RIN-value (measured with Bioanalyzer
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The results from the microarray analysis are illustrated
in Additional file 3: Plots illustrating the effect of HR
MAS MRS on the transcriptome. Hierarchical clustering
of the microarray data show that the samples cluster in
pairs. Using a false discovery rate of 0.01, 1199 tran-
scripts were significantly differentially expressed in sam-
ples that had been subjected to the HR MAS MRS
procedure (865 lower and 334 higher, detailed results in
Additional file 4: Significantly lower expressed tran-
scripts after HR MAS MRS and Additional file 5: Signif-
icantly higher expressed transcripts after HR MAS MRS
). Only 15 of the 1199 transcripts have an estimated
log2 fold change larger than 1. Among the 1199 tran-
scripts, several GO-terms were enriched, like “RNA
metabolic process” and “Regulation of gene expression”
for the transcripts higher expressed after HR MAS MRS
and “Protein localization”, “Vesicle mediated transport”
and “Tricarboxylic acid cycle” for the transcripts lower
expressed after HR MAS MRS. The 1199 significantly
differentially expressed transcripts were removed from
the microarray data of the 46 samples in the main study.
Discussion
In this study, we have shown the feasibility of merging
transcriptomics and metabolomics data from the very
same tumor tissue sample. Two strategies of combining
microarray data and HR MAS MR spectra are pre-
sented, providing a framework for how information
from these different molecular levels can be combined
Figure 2 Metabolic subtyping of luminal A samples using hierarchical clustering. The HR MAS MR spectra of the samples classified as
luminal A (N = 31), cluster in three groups using hierarchical clustering with Spearman’s correlation as the distance measure and complete
linkage. The mean spectra of each luminal A group are shown. Selected metabolite allocations are indicated with abbreviations (b-Glc: b-glucose;
Lac: lactate; Cr: creatine; m-Ino: myo-inositol; a-H: a-H of amino acids; Gly: glycine; a-Glc: a-glucose; Tau: taurine; Cho: choline; GPC:
glycerophosphocholine; PCho: phosphocholine; Ala: alanine). The spectral chemical shift-scale is non-continuous due to deletion of signals from
lipid residues at 2.8 ppm and 2.05 ppm.
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which showed slightly alterede x p r e s s i o na f t e rt h eH R
MAS MRS procedure, but overall this variation was
smaller than the biological variation in tumors from one
patient to another.
In the first strategy to combine gene expression
microarray data and HR MAS MR spectra, the expres-
sion of “intrinsic” genes was used to classify the samples
into established molecular subtypes. The HR MAS MR
spectra of the majority of tumor samples, which were
classified as luminal A, were further explored to investi-
gate whether metabolic characteristics could define sub-
groups within a transcriptionally homogenous set of
samples. The use of spin echo acquired spectral profiles
ensured a more extensive use of metabolic information
than using calculated tissue metabolite concentrations,
which is limited by several peak areas being non-quanti-
fiable. Three subgroups of luminal A tumors were iden-
tified (Figure 2 and 3). The fact that samples cluster
together differently with respect to the transcriptional
and metabolic profiles (results not shown), indicates
that microarrays and HR MAS MRS reflect different
traits of the tumors. Lower levels of glucose, which may
reflect high energy consumption, and higher levels of
alanine in A2 compared with the other luminal A sam-
ples indicate that the A2 subgroup has a higher War-
burg effect [23]. The lactate signal in A2 also appears to
be higher than in the other groups, although not at the
significance threshold level. From the GO enrichment
analysis, the A2 group was found to be enriched for
processes related to cell cycle and DNA repair, com-
pared to A1. The presented subclassification of luminal
A might have identified a subgroup of patients (A2)
with a more aggressive breast cancer, based on the
metabolic and transcriptional profile. However, since
t h i sg r o u pi ss m a l la n dn ol o n gt e r mc l i n i c a lf o l l o w - u p
is yet available for these patients, a larger cohort with
clinical data needs to be analyzed in order to validate
whether this finding has clinical impact. It should be
noted that intrinsic molecular subtyping is sensitive for
selection bias in the cohort analyzed, because of the
required gene centring of the microarray data prior to
classification. All samples were therefore included in the
intrinsic molecular classification, resulting in 10% ER
negative samples which is slightly lower than the typical
ER negative frequency in IDC. All samples classified as
Figure 3 Multidimensional scaling of the HR MAS MR spectra of the luminal A samples. Multidimensional scaling of the HR MAS MR
spectra of 31 luminal A samples, colored according to the A1-A3 subgroups found by hierarchical clustering.
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positive (3 samples were PgR negative and 1 sample had
no IHC data for PgR), which supports the classification
since luminal A samples are mostly ER/PgR positive and
typically 40-50% of IDCs are classified as luminal A [5].
Even though these preliminary results revealing meta-
bolic subgroups within luminal A tumors need to be
reproduced in a larger cohort, they suggest that micro-
array and HR MAS MRS data complement each other,
which can be exploited both in subclassification and for
constructing predictors of outcome or treatment
response.
The second strategy to combine gene expression
microarrays and HR MAS MRS was performed by cor-
relating metabolite concentration and gene expression.
In this approach, we have not focused on any specific
pathways, but correlated the metabolite concentrations
to all transcripts on the microarray that showed some
variation across samples. We excluded samples with ER
negative status from this analysis to avoid detecting
associations related to ER-status, which is known to
have a profound effect on the transcriptional profile
[24]. The three ER positive samples that were not classi-
fied as luminal A were classified as normal-like. Since
the gene expression of these three samples also corre-
l a t e dt ot h ep u b l i s h e dl u m i n a lAc e n t r o i d[ 1 7 ] ,t h e y
were included in the correlation analyses to increase
power. The gene transcripts that correlated the most to
the concentration of taurine and myo-inositol were
enriched for GO-terms associated to extracellular pro-
cesses, which could reflect a tumor-stroma interaction.
“Cell adhesion” was also one of the enriched GO-terms
for the gene transcripts that correlated to myo-inositol,
which supports this hypothesis. Taurine and myo-inosi-
t o la r ek n o w nt ob ei n v o l v e di no s m o r e g u l a t i o na n d
volume regulation [25]. It should be noted that the con-
centrations of taurine and myo-inositol correlated nega-
tively to tumor percentage (Additional file 2: Scatterplot
of metabolite concentrations and tumor percentage),
which could contribute to the apparent association of
these metabolites to extracellular processes. Gene tran-
scripts that correlated the most to choline concentration
were enriched for cell cycle related GO-terms which
indicate that the choline level in these samples reflects
proliferation. Choline is involved in glycerophospholipid
metabolism and is a nutrient taken up by the cells as
well as a breakdown product from phosphatidylcholine.
The total choline signal can be detected by in vivo MRS,
Figure 4 Differences in metabolic and gene expression profiles of identified groups of luminal A samples.M e a ns p e c t r ao ft h eA 1
(black), A2 (red) and A3 (blue) groups of luminal A tumors are plotted with the significantly different points (p < 0.001) indicated with grey
vertical lines. At ppm values with allocated metabolites and significant differences in one group versus the other, the direction of the arrows
indicate if the latter group has the highest (up) or lowest (down) mean value. GO-terms that were significantly enriched (fdr < 0.01) in the
different groups are indicated for each comparison, calculated using Gene Set Analysis (GSA) on the microarray data.
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Page 9 of 14Figure 5 Correlation analysis for myo-inositol and choline. The concentration of (A) myo-inositol and (B) choline is plotted for the ER
positive samples (n = 34), which are ordered according to concentration. The expression of the 30 transcripts that correlated most to these
metabolites are shown as heatmaps (see color bar for scale), ordered according to Spearman’s rank correlation coefficient. The samples for which
the microarray data were obtained from RNA extracted from adjacent tumor tissue are labeled with the prefix “adj”.
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Page 10 of 14Table 2 GO enrichment analysis of genes that correlated to the quantified metabolites, using GOrilla
Metabolite/GO-
category
GO-Term Description P-
value
Enrichment (N,B,n,b)
myo-Inositol
BP GO:0032502 developmental process 6.40E-
10
1.45 (7307,1397,864,240)
BP GO:0030198 extracellular matrix organization 1.00E-
09
7.16 (7307,56,310,17)
BP GO:0007155 cell adhesion 1.20E-
08
2.45 (7307,377,412,52)
BP GO:0022610 biological adhesion 1.40E-
08
2.44 (7307,378,412,52)
BP GO:0043062 extracellular structure organization 2.20E-
07
4.92 (7307,86,311,18)
MF GO:0005201 extracellular matrix structural constituent 2.10E-
09
7.39 (7307,51,310,16)
CC GO:0005576 extracellular region 3.80E-
21
2.76 (7307,885,311,104)
CC GO:0044421 extracellular region part 7.10E-
17
2.28 (7307,513,757,121)
CC GO:0031012 extracellular matrix 5.30E-
15
5.34 (7307,159,310,36)
CC GO:0005578 proteinaceous extracellular matrix 2.90E-
14
5.57 (7307,142,305,33)
CC GO:0044420 extracellular matrix part 2.30E-
10
3.44 (7307,71,986,33)
CC GO:0005581 collagen 1.60E-
08
21.83 (7307,26,103,8)
Taurine
BP GO:0032502 developmental process 8.20E-
08
1.48 (7307,1397,630,178)
BP GO:0048731 system development 1.90E-
07
2.23 (7307,314,554,53)
MF GO:0005201 extracellular matrix structural constituent 6.20E-
10
16.25 (7307,51,97,11)
CC GO:0044421 extracellular region part 8.30E-
14
2.44 (7307,513,485,83)
CC GO:0005576 extracellular region 3.90E-
12
2.35 (7307,885,267,76)
CC GO:0031012 extracellular matrix 2.60E-
10
3.43 (7307,159,482,36)
CC GO:0044420 extracellular matrix part 1.80E-
09
12.73 (7307,71,97,12)
CC GO:0005578 proteinaceous extracellular matrix 2.10E-
09
3.52 (7307,142,482,33)
CC GO:0005581 collagen 5.10E-
08
9.48 (7307,26,326,11)
Choline
BP GO:0090304 nucleic acid metabolic process 2.00E-
09
1.75 (7307,497,990,118)
BP GO:0022402 cell cycle process 2.30E-
08
2.09 (7307,239,952,65)
BP GO:0007059 chromosome segregation 3.90E-
07
4.65 (7307,25,943,15)
BP GO:0006139 nucleobase, nucleoside, nucleotide and nucleic acid metabolic
process
8.80E-
07
1.54 (7307,640,994,134)
CC GO:0044428 nuclear part 9.80E-
11
1.7 (7307,632,999,147)
CC GO:0005634 nucleus 5.80E-
09
1.3 (7307,2062,990,364)
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Page 11 of 14and is elevated in breast cancer compared to normal
mammary tissue and benign lesions [26]. No signifi-
cantly enriched GO-terms were found in the genes that
correlated the most to the two other choline metabolites
involved in the total choline peak, PCho and GPC. Glu-
cose correlated to genes that were significantly enriched
for the GO-term “immune system process”.G l u c o s e
concentration has been shown to have an inverse rela-
tionship to the number of proliferating cells [27] and
tumor cell density [28]. For creatine, only the GO-term
“mannosyltransferase activity”, which is a glycosylation
process, was significantly enriched among the genes that
correlated to the metabolite. The genes that correlated
to the amino acid glycine, were also only significantly
enriched for one GO-term, “respiratory chain”, suggest-
ing a possible association between aerobic respiration
and glycine levels in these tumor samples. However, gly-
cine was the only metabolite that showed significant
positive correlation to tumor percentage (Additional file
2: Scatterplot of metabolite concentrations and tumor
percentage.), which could have influenced this relation-
ship. It is worth noting that few transcripts showed a
strong correlation to the eight metabolites, as can be
s e e ni nt h ee x a m p l e si nF i g u r e5 .S i n c em e t a b o l i t ec o n -
centrations reflect the sum of many different pathways,
correlating the expression of single genes to metabolites
is probably not the optimal way to compare the tran-
scriptional and metabolic profiles of tumors. The fact
that the most correlated genes were not directly asso-
ciated with the metabolic pathways of the metabolites
they correlated to also emphasizes the complexity of the
relationships between gene expression levels and meta-
bolite concentrations. Improved quantification of tissue
metabolite concentrations using ERETIC [27] or dieretic
[29] and more refined approaches for data analysis, pos-
sibly involving curated metabolic pathways, should be
explored in the future when larger datasets of
microarray and HR MAS MRS data from the same
tumor samples can be obtained, with corresponding
clinical information.
MRS and microarray experiments have not previously
been performed on the same breast cancer sample from
the same patient. A study by Tzika et al. combined gene
expression microarrays and HR MAS MRS on the same
sample of brain tumor and control biopsies [30]. How-
ever, no results were reported of combining these two
types of information, except for stating that a number of
transcripts correlated well to the measured metabolites.
Breast cancer biology is highly complex, which is
reflected at many different molecular levels. Using gene
expression microarray and HR MAS MRS data from the
very same tumor sample can reduce the biological var-
iance which gives a higher power to study the transcrip-
tional and metabolic levels in a combined approach.
Even though HR MAS MRS leaves the tumor tissue
intact, the procedure exposes the tissue to several
potential stresses, including hypoxic conditions and lack
of nutrients by being embedded in a surrounding buffer
at 4°C for approximately an hour, as well as high centri-
fugal force and magnetic field during the HR MAS MRS
acquisition. In our parallel study to address this issue,
total RNA integrity was not significantly affected by HR
MAS MRS (p-value = 0.86), and findings in a similar
evaluation in prostate tissue support this result [31].
The pairs of tumor samples from each patient that had
or had not been analyzed by HR MAS MRS cluster
together (Additional file 3: Plots illustrating the effect of
HR MAS MRS on the transcriptome), indicating that
patient to patient variation is larger than the effect of
HR MAS MRS. Even though 1199 transcripts were
defined as differentially expressed (fdr < 0.01) by HR
MAS MRS, these transcripts showed a small fold
change. In their study of prostate tissue, Santos et al.
reported no differential expression caused by HR MAS
Table 2 GO enrichment analysis of genes that correlated to the quantified metabolites, using GOrilla (Continued)
CC GO:0000775 chromosome, centromeric region 2.50E-
08
10.2 (7307,26,303,11)
Glucose
BP GO:0002376 immune system process 1.60E-
09
1.83 (7307,420,999,105)
Creatine
MF GO:0000030 mannosyltransferase activity 5.80E-
08
73.81 (7307,4,99,4)
Glycine
CC GO:0070469 respiratory chain 5.80E-
07
4.74 (7307,22,981,14)
GO-terms in the Biological Process (BP), Molecular Function (MF) and Cellular Compartment (CC) categories that were significantly enriched (p-value < 10E-7)
towards the top of the lists of transcripts ranked according to correlation to each of the quantified metabolites. Enrichment is defined as (b/n)/(B/N), where N is
the total number of genes, B is the total number of genes associated with a specific GO term, n is the number of genes in the “target set”, b is the number of
genes in the “target set” associated with a specific GO term [21]. The p-value threshold corresponds to fdr = 8 metabolites * (877 CC GO-terms*10^-7 + 2416 MF
GO-terms*10^-7 + 6307 BP GO-terms*10^-7)/31 significant GO terms = 0.003. There were no significantly enriched GO-terms associated with GPC or PCho.
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Page 12 of 14MRS [31]. However, Santos et al.u s e dc D N Am i c r o a r -
ray data from unpaired samples to test for differential
expression. The patient heterogeneity might have been
too high to achieve the power needed to detect possible
changes in gene expression in their study.
Conclusions
Performing HR MAS MRS and microarray analysis on
the same sample is feasible, and the effect of HR MAS
MRS on the transcriptome was shown to be subtle.
Three subgroups of samples within the most prevalent
intrinsic subgroup of breast cancer, luminal A, were
found using multivariate analyses of HR MAS MRS
spectra. One of the subgroups of luminal A samples,
designated A2, had metabolic and transcriptional fea-
tures indicating a higher Warburg effect and more pro-
liferation than the other luminal A groups. Using a
different strategy, enrichment analysis of genes with
expression levels that correlated to metabolite concen-
trations revealed different enriched GO-terms associated
with specific metabolites. GO-terms related to the extra-
cellular matrix were enriched among the genes that cor-
related the most to myo-inositol and taurine, while cell
cycle related GO-terms were enriched among the genes
that correlated the most to choline. We have shown
that combining transcriptional and metabolic data from
the same breast carcinoma sample can contribute to a
more refined subclassification of breast cancers as well
as reveal relationships between these molecular levels.
This study has paved the way for further studies in lar-
ger patient cohorts of all subtypes, correlating metabolic
subgroups to histopathological characteristics, treatment
response and clinical outcome.
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GO: Gene Ontolgy; MDS: multidimensional scaling;
GSA: Gene Set Analysis
Additional material
Additional file 1: Supplementary documentation of exploring the
effect of HR MAS MRS on RNA integrity and transcription. Additional
documentation of the experimental procedure and data analysis
involving the 18 pairs of samples used in the parallel study to assess the
feasibility of performing HR MAS MRS and gene expression microarrays
on the same samples.
Additional file 2: Scatterplot of metabolite concentrations and
tumor percentage. The log2 of the tissue concentrations (μmol/gram)
of glycerophosphocholine (GPC), glycine, phosphocholine (PCho),
creatine, choline, taurine, myo-inositol and glucose as well as the tumor
percentage (Tumor) are plotted against each other in the upper diagonal
panel. Spearman’s rank correlation coefficients are given in the lower
diagonal panel. Significant (p < 0.05) correlations are indicated by bold
font. The values on the axes represent log2 tissue concentrations (μmol/
gram), except for the Tumor axis which represents percentage.
Additional file 3: Plots illustrating the effect of HR MAS MRS on the
transcriptome. (A) Hierarchical clustering of the 18 pairs of tumors
before (control) and after HR MAS (HRMAS). (B) A plot of the number of
significantly differentially expressed (DE) genes caused by HR MAS MRS
as a function of false discovery rate. Bonferroni corrected p-value = 0.05
is indicated in the plot. (C) A volcanoplot of significance versus the
estimated fold change caused by HR MAS MRS. Transcripts with fdr <
0.01 are colored red or blue to indicate higher or lower expression after
HR MAS MRS, respectively. The top Biological Process GO-terms of the
differentially expressed genes are listed on each side with the same
color-code.
Additional file 4: Significantly lower expressed transcripts after HR
MAS MRS. A summary of the 865 transcripts with significantly lower
expression after HR MAS MRS, identified using Limma (R/Bioconductor).
The columns ProbeUID, AgilentProbeID, GeneSymbol, SystematicName
are annotations as given by Agilent. The columns logFoldChange,
AverageExpression, t.statistic, p.value and adjusted.p.value are the results
from the modified paired t-tests performed by Limma.
Additional file 5: Significantly higher expressed transcripts after HR
MAS MRS. A summary of the 334 transcripts with significantly higher
expression after HR MAS MRS, identified using Limma (R/Bioconductor).
The columns ProbeUID, AgilentProbeID, GeneSymbol, SystematicName
are annotations as given by Agilent. The columns logFoldChange,
AverageExpression, t.statistic, p.value and adjusted.p.value are the results
from the modified paired t-tests performed by Limma.
Acknowledgements
Grant sponsors: The Norwegian Research Council, grant numbers 175459
and 183379, and 163027. St. Olavs University Hospital Cancer Foundation.
Author details
1Department of Genetics, Institute for Cancer Research, Division of Surgery
and Cancer, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
2Department of Circulation and Medical Imaging, Norwegian University of
Science and Technology (NTNU), Trondheim, Norway.
3Biomedical Research
Group, Department of Informatics, University of Oslo, Oslo, Norway.
4Department of Oncology, St. Olavs University Hospital Trondheim,
Trondheim, Norway.
5Institute of Clinical Medicine, Faculty of Medicine,
University of Oslo, Norway.
Authors’ contributions
EB carried out HR MAS MRS and microarray experiments and performed
microarray preprocessing, data analysis and interpretation of HR MAS MRS
and microarray data, and drafted the manuscript. BS performed HR MAS MRS
and microarray experiments, did the preprocessing of the HR MAS MRS data,
contributed to analysis and interpretation of HR MAS MRS and microarray
data and drafting of the manuscript. OCL contributed to analysis and
interpretation of HR MAS MRS and microarray data. HJ carried out microarray
experiments. TB contributed to interpretation of HR MAS MRS and microarray
data. TS contributed to analysis and interpretation of microarray data. SL
provided tumor material and clinical data. ALBD conceived of the study, and
participated in its design and helped drafting the manuscript. ISG conceived
of the study and participated in its design and coordination. All authors
revised the manuscript and approved the final version.
Competing interests
The authors declare that they have no competing interests.
Received: 11 May 2010 Accepted: 16 November 2010
Published: 16 November 2010
Borgan et al. BMC Cancer 2010, 10:628
http://www.biomedcentral.com/1471-2407/10/628
Page 13 of 14References
1. Cianfrocca M, Goldstein LJ: Prognostic and predictive factors in early-
stage breast cancer. Oncologist 2004, 9:606.
2. Sotiriou C, Piccart MJ: Taking gene-expression profiling to the clinic:
when will molecular signatures become relevant to patient care? Nat
Rev Cancer 2007, 7:545-553.
3. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR,
Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C,
Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular
portraits of human breast tumours. Nature 2000, 406:747-752.
4. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T,
Eisen MB, van de RM, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO,
Botstein D, Eystein LP, Borresen-Dale AL: Gene expression patterns of
breast carcinomas distinguish tumor subclasses with clinical
implications. Proc Natl Acad Sci USA 2001, 98:10869-10874.
5. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S,
Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE,
Brown PO, Borresen-Dale AL, Botstein D: Repeated observation of breast
tumor subtypes in independent gene expression data sets. Proc Natl
Acad Sci USA 2003, 100:8418-8423.
6. Sorlie T, Wang YL, Xiao CL, Johnsen H, Naume B, Samaha RR, Borresen-
Dale AL: Distinct molecular mechanisms underlying clinically relevant
subtypes of breast cancer: gene expression analyses across three
different platforms. BMC Genomics 2006, 7:127.
7. Lindon JC, Beckonert OP, Holmes E, Nicholson JK: High-resolution magic
angle spinning NMR spectroscopy: Application to biomedical studies.
Prog Nucl Magn Reson Spectrosc 2009, 55:79-100.
8. Sitter B, Bathen T, Tessem MB, Gribbestad IS: High-resolution magic angle
spinning (HR MAS) MR spectroscopy in metabolic characterization of
human cancer. Prog Nucl Magn Reson Spectrosc 2009, 54:239-254.
9. Eliyahu G, Kreizman T, Degani H: Phosphocholine as a biomarker of breast
cancer: molecular and biochemical studies. Int J Cancer 2007,
120:1721-1730.
10. Glunde K, Jie C, Bhujwalla ZM: Molecular causes of the aberrant choline
phospholipid metabolism in breast cancer. Canc Res 2004, 64:4270-4276.
11. Moestue S, Borgan E, Huuse E, Lindholm E, Sitter B, Borresen-Dale AL,
Engebraaten O, Maelandsmo G, Gribbestad I: Distinct choline metabolic
profiles are associated with differences in gene expression for basal-like
and luminal-like breast cancer xenograft models. BMC Cancer 2010,
10:433.
12. Morse DL, Carroll D, Day S, Gray H, Sadarangani P, Murthi S, Job C,
Baggett B, Raghunand N, Gillies RJ: Characterization of breast cancers and
therapy response by MRS and quantitative gene expression profiling in
the choline pathway. NMR Biomed 2009, 22:114-127.
13. Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS:
Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue
with clinical parameters. NMR Biomed 2006, 19:30-40.
14. Sitter B, Sonnewald U, Spraul M, Fjosne HE, Gribbestad IS: High-resolution
magic angle spinning MRS of breast cancer tissue. NMR Biomed 2002,
15:327-337.
15. Smyth GK: Linear models and empirical bayes methods for assessing
differential expression in microarray experiments. Stat Appl Genet Mol Biol
2004, 3:Article 3.
16. Stacklies W, Redestig H, Scholz M, Walther D, Selbig J: pcaMethods–a
bioconductor package providing PCA methods for incomplete data.
Bioinformatics 2007, 23:1164-1167.
17. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA,
Reynolds E, Dressler L: The molecular portraits of breast tumors are
conserved across microarray platforms. BMC Genomics 2006, 7:96.
18. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP,
Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A,
Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G: Gene
ontology: tool for the unification of biology. The Gene Ontology
Consortium. Nat Genet 2000, 25:25-29.
19. Gene Set Analysis. [http://www-stat.stanford.edu/~tibs/GSA/].
20. Eden E, Lipson D, Yogev S, Yakhini Z: Discovering motifs in ranked lists of
DNA sequences. PLoS Comput Biol 2007, 3:e39.
21. Eden E, Navon R, Steinfeld I, Lipson D, Yakhini Z: GOrilla: a tool for
discovery and visualization of enriched GO terms in ranked gene lists.
BMC Bioinformatics 2009, 10:48.
22. Falcon S, Gentleman R: Using GOstats to test gene lists for GO term
association. Bioinformatics 2007, 23:257-258.
23. Vander Heiden MG, Cantley LC, Thompson CB: Understanding the
Warburg effect: the metabolic requirements of cell proliferation. Sci
Signal 2009, 324:1029.
24. Gruvberger S, Ringnér M, Chen Y, Panavally S, Saal LH, Borg A, Ferno M,
Peterson C, Meltzer PS: Estrogen receptor status in breast cancer is
associated with remarkably distinct gene expression patterns. Canc Res
2001, 61:5979.
25. Griffin JL, Shockcor JP: Metabolic profiles of cancer cells. Nat Rev Cancer
2004, 4:551-561.
26. Kvistad KA, Bakken IJ, Gribbestad IS, Ehrnholm B, Lundgren S, Fjosne HE,
Haraldseth O: Characterization of neoplastic and normal human breast
tissues with in vivo 1H MR spectroscopy. J Magn Reson Imaging 1999,
10:159-164.
27. Sitter B, Bathen TF, Singstad TE, Fjosne HE, Lundgren S, Halgunset J,
Gribbestad IS: Quantification of metabolites in breast cancer patients
with different clinical prognosis using HR MAS MR spectroscopy. NMR
Biomed 2010, 23:424-31.
28. Lyng H, Sitter B, Bathen TF, Jensen LR, Sundfør K, Kristensen GB,
Gribbestad IS: Metabolic mapping by use of high-resolution magic angle
spinning 1 H MR spectroscopy for assessment of apoptosis in cervical
carcinomas. BMC Cancer 2007, 7:11.
29. Wider G, Dreier L: Measuring protein concentrations by NMR
spectroscopy. J Am Chem Soc 2006, 128:2571-2576.
30. Tzika AA, Astrakas L, Cao H, Mintzopoulos D, Andronesi OC, Mindrinos M,
Zhang J, Rahme LG, Blekas KD, Likas AC, Galatsanos NP, Carroll RS,
Black PM: Combination of high-resolution magic angle spinning proton
magnetic resonance spectroscopy and microscale genomics to type
brain tumor biopsies. Int J Mol Med 2007, 20:199-208.
31. Santos CF, Kurhanewicz J, Tabatabai ZL, Simko JP, Keshari KR, Gbegnon A,
Santos RD, Federman S, Shinohara K, Carroll PR, Haqq CM, Swanson MG:
Metabolic, pathologic, and genetic analysis of prostate tissues:
quantitative evaluation of histopathologic and mRNA integrity after HR-
MAS spectroscopy. NMR Biomed 2009, 23:391-8.
32. Strand C, Enell J, Hedenfalk I, Ferno M: RNA quality in frozen breast
cancer samples and the influence on gene expression analysis–a
comparison of three evaluation methods using microcapillary
electrophoresis traces. BMC Mol Biol 2007, 8:38.
33. Falcon S, Gentleman R: Using GOstats to test gene lists for GO term
association. Bioinformatics 2007, 23:257-258.
34. Efron B, Tibshirani R: Empirical Bayes methods and false discovery rates
for microarrays. Genet Epidemiol 2002, 23:70-86.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/10/628/prepub
doi:10.1186/1471-2407-10-628
Cite this article as: Borgan et al.: Merging transcriptomics and
metabolomics - advances in breast cancer profiling. BMC Cancer 2010
10:628.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Borgan et al. BMC Cancer 2010, 10:628
http://www.biomedcentral.com/1471-2407/10/628
Page 14 of 14